Wealthfront (WLTH) earns a Strong Buy: low valuation, strong balance sheet, user growth, and buybacks amid macro risks.
The price of weight-loss drugs has been dropping in 2026. At the same time, employers have been cutting back on their coverage of the drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results